MK-7240
MK-7240 (formerly PRA-023) is a humanized monoclonal antibody developed for ulcerative colitis and Crohn's disease.[1][2][3] Before the company was acquired by Merck for $10.8 billion, it was developed by Prometheus Biosciences.[4]
References
[edit]- ^ Tubau-Juni, Nuria; Hontecillas, Raquel; Leber, Andrew J; Alva, Sameeksha S; Bassaganya-Riera, Josep (2 November 2023). "Treating Autoimmune Diseases With LANCL2 Therapeutics: A Novel Immunoregulatory Mechanism for Patients With Ulcerative Colitis and Crohn's Disease". Inflammatory Bowel Diseases. doi:10.1093/ibd/izad258.
- ^ Feagan, B G; Sands, B; Siegel, C A; Dubinsky, M; Longman, R; Sabinho, J; Laurent, O; Luo, A; Lu, J D; Nguyen, D; Towfic, F; DuVall, A; Woyranowski, M; Al Kharrat, H; McGovern, D P B (30 January 2023). "DOP87 The Anti-TL1A Antibody PRA023 Demonstrated Proof-of-Concept in Crohn's Disease: Phase 2a APOLLO-CD Study Results". Journal of Crohn's and Colitis. 17 (Supplement_1): i162–i164. doi:10.1093/ecco-jcc/jjac190.0127.
- ^ Sands, B; Peyrin-Biroulet, L; Danese, S; Rubin, D T; Vermeire, S; Laurent, O; Luo, A; Nguyen, D; Lu, J D; Wiechowska-Kozlowska, A; Leszczyszyn, J; Kempinski, R; Kierkus, J; Ma, C; Ritter, T; Feagan, B G; Targan, S (30 January 2023). "OP40 PRA023 Demonstrated Efficacy and Favorable Safety as Induction Therapy for Moderately to Severely Active UC: Phase 2 ARTEMIS-UC Study Results". Journal of Crohn's and Colitis. 17 (Supplement_1): i56–i59. doi:10.1093/ecco-jcc/jjac190.0040.
- ^ "Merck Closes Prometheus Acquisition". San Diego Business Journal. 24 June 2023. Retrieved 20 November 2023.